The correct answer is B because off-label control in the visit experience is tied to product detailing behavior. In life sciences commercial engagement, product detailing governs what products, messages, indications, and approved content can be discussed or shown during a visit. Salesforce Trailhead describes Life Sciences Cloud content visibility as being filtered by territory, product assignment, and account restrictions to prevent off-label or noncompliant sharing. This aligns most closely with Visit Settings > Product Detailing Settings, because that is the visit configuration area where product discussion and detailing behavior is controlled.
The question asks where the consultant should configure whether reps are allowed to discuss products for unapproved indications. That is not a generic compliance switch; it is a visit-detailing control connected to product and indication behavior in the field engagement workflow. Product Detailing Settings are therefore the correct place to enforce whether off-label discussion is permitted, warned, or restricted according to company policy.
Option A is incorrect because "Compliance Settings > Off-Label Validation" is not the standard configuration path presented in the available options for the Life Sciences visit experience. Option C is also incorrect because Restricted Products would control whether products are available or restricted, but the scenario is specifically about discussion of unapproved indications during product detailing. Therefore, the consultant should use Visit Settings > Product Detailing Settings.
=========